



Schizophrenia: A Short Review

Kiran Mayee K *

Department of Pharmaceutical Analysis & Quality Assurance, Osmania University, Telangana, India

***Corresponding author:** Kiran Mayee K, Department of Pharmaceutical Analysis & Quality Assurance, Osmania University, Telangana, India, E-mail: kondabathinilight@gmail.com

Received: Mar 08, 2017; **Accepted:** Mar 16, 2017; **Published:** April 06, 2017

Abstract

Schizophrenia is a long-lasting and severe mental condition that affects how an individual thinks, feels, and behaves relating to his/her social behavior. As a major study in Neuropsychiatry, Schizophrenia requires clear to the evaluation, differential diagnosis, prognosis, pharmacological treatment, psychosocial management, and neurorehabilitation of persons.

Keywords: Schizophrenia; Antipsychotic; Delusion; Hallucination; Disorganized behavior

Introduction

Schizophrenia is a mental disorder that generally appears in late teenage years or initial adulthood. Reflects major symptoms such as delusions, hallucinations, and other cognitive complications, schizophrenia can be a lifelong struggle [1-20].




FIG.1: Symptoms of Schizophrenia

Nearly 0.3-0.7% of individuals suffers from schizophrenia during their lifetimes. 2013 statistics show that there are estimated to be 23.6 million cases globally. Males are more prone to schizophrenia than females. The typical life prospect of people with the ailment is ten to twenty-five years less than for the general population. This is the result of increased physical health problems and a higher suicide rate (about 5%). In 2013 a projected 16,000 people globally died from behavior related to, or caused by, schizophrenia [21-40].

To create awareness of increasing Schizophrenia disorder physicians, researchers form a society or an organization. Main motto of these societies is to build awareness among the individuals of Schizophrenia for better social behaviours.

Schizophrenia societies around the globe include Schizophrenia Society of Canada with the mission of to improve the quality of life for those affected by schizophrenia and psychosis through education, support programs, public policy and research. Schizophrenia International Research Society works for the basic theme of Exchange the latest advances in research and facilitate the applications and these findings to clinical practice; Promote educational programs to effectively disseminate new research findings related to schizophrenia; Increase the public understanding of the personal, familial and societal impact of schizophrenia. British Columbia Schizophrenia Society holds a vision to serve schizophrenia and psychosis individuals to receive excellent treatment and services and are accepted and included in their communities [41-50].

Several Open Access literatures display the information and ongoing research on Schizophrenia across the globe. Neuropsychiatry (London) is the key platform for displaying various updated research in Schizophrenia studies. Journal of Neurological Disorders covers the basic knowledge and provides cutting-edge research strategies in the development of updated neurological disorders. Bipolar Disorder: Open Access is a leading provider of information on Schizophrenia studies and novel methods of treatment followed [51-70]. The above mentioned Open access journals on Neurology are the peer-reviewed journals that maintain the quality and standard of the journal content, reviewer's agreement and respective editor's acceptance in order to publish an article. These journals ensures the barrier-free distribution of its content through online open access and thus helps in improving the citations for authors and attaining good journal impact factors.

Research in Schizophrenia: A Glance

Here is the list of few articles which provide reports that are competent enough for a person to attain knowledge on Schizophrenia. An article entitled Comparison of pre-treatment clinical characteristics and post-treatment outcomes of patients treated with Clozapine and long acting antipsychotics written by Dante M Durand & colleagues, displays the comparison of pre-treatment disease severity and treatment outcome of patients receiving clozapine and long-acting antipsychotics (LAA). Research article titled: Hemispheric differences for visual P3 amplitude in patients with schizophrenia by Shahrzad Mazhari & colleagues aimed to investigate the presence and pattern of lateralization of the P3 component in a group of patients with schizophrenia. Similarly, article titled: A naturalistic comparison study of effectiveness of intramuscular olanzapine and intramuscular haloperidol in acute agitated patients with schizophrenia provides a study was a comparative investigation of the clinical effectiveness of intramuscular (IM) olanzapine, and IM haloperidol in acute agitated patients with schizophrenia. Other articles titled: Association study of suppressor with morphogenetic effect on genitalia protein 6 (SMG6) polymorphisms and schizophrenia symptoms in the Han Chinese population & The effectiveness of mindfulness-based intervention for people with schizophrenia: a systematic review provide schizophrenia research with main aim of to identify SMG6 gene polymorphisms that may confer susceptibility to SZ in a Han Chinese population & summarize and synthesize the evidence regarding the effectiveness of MBI for people with schizophrenia respectively [71-90].

Apart from the research papers & societies, presentation at conferences, symposiums, workshops also yield an updated exposure to schizophrenia information and innovative technologies that are being invented in the present generation. 2nd International Conference on Brain Disorders and Therapeutics during October 26-28, 2016 at Chicago, USA has displayed the theme of Rethinking the Brain: Spread Your Intellectual Insight in Comprehending Brain Disorders. 2nd International Conference on Neurological Disorders and Stroke during April 28-30, 2016 at Dubai, UAE has brought the exposure for Novel approaches and Developments in Neurological disorders and Stroke. 8th European Neurology Congress which is held

on September 21-23, 2016 at Amsterdam, Netherlands worked with the theme of Exploring the advancements in Neuroscience and Neurology. 2nd International Conference on Central Nervous System Disorders and Therapeutics was enlightened with the theme Accelerate the Diagnosis, Prevention & Management of CNS Disorders [91-100].

Other Conferences in 2017 with more perspectives in Schizophrenia include:

5th International Conference on Brain Disorders and Therapeutics, November 6-8, 2017, Madrid, Spain

16th International Conference on Neurology and Neuro Cognitive Disorders, October 09-10, 2017, London, UK

3rd International Conference on Parkinson's disease & Movement Disorders, September 25-26, 2017, Chicago, USA

Global Experts Meeting On Brain Disorders, September 07-08, 2017, Macau, Hong Kong.

Conclusion

Caring for and supporting a loved one with schizophrenia can be hard. It can be difficult to know how to respond to someone who makes strange or clearly false statements. It is important to understand that schizophrenia is a biological illness. Clinical trials are research studies that look at new ways to prevent, detect, or treat diseases and conditions, including schizophrenia. During clinical trials, treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Although individual participants may benefit from being part of a clinical trial, participants should be aware that the primary purpose of a clinical trial is to gain new scientific knowledge so that others may be better helped in the future. All this information can be accessed in open access health care literature which exhibits the novel techniques and innovative researches taking place in the research field. Many professionals share their views; suggestions through the open access literature which can be accessed by all in order attain knowledge on Neurodiseases.

REFERENCE

1. Lang B, Lei Zhang, Guanyu Jiang, et al. Control of cortex development by ULK4, a rare risk gene for mental disorders including schizophrenia. *Sci Rep.* 2016;6(1):31126.
2. Thomson A, Tiihonen J, Miettunen J, et al. Fire-setting performed in adolescence or early adulthood predicts schizophrenia: a register-based follow-up study of pre-trial offenders. *Nord J Psychiatry.* 2016.
3. Charles L, Gaillard R, Amado I, et al. Conscious and unconscious performance monitoring: Evidence from patients with schizophrenia. *Neuroimage.* 2016;144(Pt A):153-163.
4. Scotti-Muzzi E, Saide OL. Schizo-obsessive spectrum disorders: an update. *CNS Spectr.* 2016;27(1):1-15.
5. Uran P, Yürümez E, Aysev A, et al. Premenstrual syndrome health-related quality of life and psychiatric comorbidity in a clinical adolescent sample: a cross-sectional study. *Int J Psychiatry Clin Pract.* 2016;21(1):36-40.
6. Pan S, Tan Y, Yao S, et al. Serum high-sensitivity C-reactive protein: A delicate sentinel elevated in drug-free acutely agitated patients with schizophrenia. *Psychiatry Res.* 2016;246(1):89-94.
7. Hurtado MM, Triviño M, Arnedo M, et al. Are executive functions related to emotional intelligence? A correlational study in schizophrenia and borderline personality disorder. *Psychiatry Res.* 2016;246(1):84-88.
8. Cotovio G, Velosa A, Oliveira-Maia AJ, et al. Clozapine-Resistant Schizophrenia Treated With Ultra-brief Pulse, Unilateral Electroconvulsive Therapy. *J ECT.* 2017;33(1):e3-e4.

9. Kahn JR, Collinge W, Soltysik R. Post-9/11 Veterans and Their Partners Improve Mental Health Outcomes with a Self-directed Mobile and Web-based Wellness Training Program: A Randomized Controlled Trial. *J Med Internet Res.* 2016;18(9):e255.
10. Pos K, Boyette LL, Meijer CJ, et al. The effect of childhood trauma and Five-Factor Model personality traits on exposure to adult life events in patients with psychotic disorders. *Cogn Neuropsychiatry.* 2016;21(6):462-474.
11. Costa EC, Guimarães S, Ferreira D, et al. Resource Loss Moderates the Association Between Child Abuse and Current PTSD Symptoms Among Women in Primary-Care Settings. *J Interpers Violence.* 2016.
12. Scarff JR. Brexpiprazole: A New Treatment Option for Schizophrenia. *Innov Clin Neurosci.* 2016;13(7-8):26-29.
13. MacEwan JP, Seabury S, Aigbogun MS, et al. Pharmaceutical Innovation in the Treatment of Schizophrenia and Mental Disorders Compared with Other Diseases. *Innov Clin Neurosci.* 2016;13(7-8):17-25.
14. Zaky EA, Fouda EM, Nabih ES, et al. Association of Second Hand Smoking with Mental Disorders in Children- An Egyptian Study. *J Psychol Abnorm Child.* 2015;4:140.
15. Ponizovsky AM and Mansbach-Kleinfeld I. Prevalence of Mental Disorders and Use of Services in an Immigrant Adolescent Population: Findings from a National Mental Health Survey. *J Child Adolesc Behav.* 2015;3:176.
16. Alavi N, Roberts N, DeGrace E. Outcome Study of Intensive Day Treatment for Children with Pervasive Developmental Disorders. *Autism Open Access.* 2014;4:137.
17. Karhson DS, Hardan AY, Parker KJ. Endocannabinoid signaling in social functioning: an RDoC perspective. *Transl Psychiatry.* 2016;6(9): e905.
18. Detke HC, Melissa DP, John L, et al. A 52-Week Study of Olanzapine with a Randomized Behavioral Weight Counseling Intervention in Adolescents with Schizophrenia or Bipolar I Disorder. *J Child Adolesc Psychopharmacol.* 2016;26(10):922-934.
19. Kageyama Y, Kasahara T, Morishita H, et al. Search for plasma biomarkers in drug-free patients with bipolar disorder and schizophrenia using metabolome analysis. *Psychiatry Clin Neurosci.* 2016;71(2):115-123.
20. Morita K, Miura K, Fujimoto M, et al. Eye Movement as a Biomarker of Schizophrenia: Using an Integrated Eye Movement Score. *Psychiatry Clin Neurosci.* 2016;71(2):104-114.
21. Gay O, Plaze M, Oppenheim C, et al. Cognitive control deficit in patients with first-episode schizophrenia is associated with complex deviations of early brain development. *J Psychiatry Neurosci.* 2016;41(6):150267.
22. Scheinost D, Sinha R, Cross SN, et al. Does prenatal stress alter the developing connectome? *Pediatr Res.* 2016;81(1-2):214-226.
23. Haider AS, Alam M, Adetutu E, et al. Autoimmune Schizophrenia? Psychiatric Manifestations of Hashimoto's Encephalitis. *Cureus.* 2016;8(7):e672.
24. Karkhane Yousefi M, Folsom TD, Fatemi SH. A Review of Varenicline's Efficacy and Tolerability in Smoking Cessation Studies in Subjects with Schizophrenia. *J Addict Res Ther.* 2011;S4.
25. Kerebih H, Soboka M. Prevalence of Common Mental Disorders and Associated Factors among Residents of Jimma Town, Southwest Ethiopia. *J Psychiatry.* 2016;19:373.
26. Sun X, Wang Y, Jiang N, et al. The Potential Role of Melatonin on Mental Disorders: Insights from Physiology and Pharmacology. *Bipolar Disord.* 2016; 2:105.

27. Oga H, Yoshimasu K. A Pilot Study of Self-Care Program of Mindful Life Approach for Improvements of Socially Problematic Behaviors of Children with Developmental Disorders through Caregivers. *J Psychol Psychother.* 2016;6:245.
28. Horowitz-Kraus T. All Roads Lead to Rome? Distinct Neural Circuits in Different Developmental Disorders are Related to Reading Difficulties in Children. *Brain Disord Ther.* 2015;4:197.
29. Castaldo M. Susto: Etiology of Mental Disorders in Mothers and Children in Mexico. *J Preg Child Health.* 2015; 2:206.
30. Tibebe A, Tesfay K. Public Knowledge and Beliefs about Mental Disorders in Developing Countries: A Review. *J Depress Anxiety.* 2015;S3:004.
31. de Oliveira RM, Santos JLF, Furegato ARF. Factors Associated With Tobacco Dependence in People with Mental Disorders. *J Addict Res Ther.* 2015;6:231.
32. Yamagishi S, Mikawa S, Furukawa H, et al. Spine Homeostasis as a Novel Therapeutic Target for Schizophrenia. *Clin Pharmacol Biopharm.* 2013;S1:001.
33. Sandy PT, Mgutshini T. Integrating Religiosity into Motivational Interviewing and Nicotine Replacement Therapy for a Patient with Schizophrenia and Nicotine Addiction: Lessons from a Mental Health Service. *J Addict Res Ther.* 2012;3:127.
34. Mas-Expósito L, Mazo AE, San Emeterio M, et al. Physical Health and Schizophrenia in Clinical Practice Guidelines and Consensus Statements. *J Addict Res Ther.* 2012;S8:001.
35. Ikemoto K. Are D-Neurons and Trace Amine-Associated Receptor, Type 1 Involved in Mesolimbic Dopamine Hyperactivity of Schizophrenia?. *Med Chem (Los Angeles).* 2012; 2:038-040.
36. Grover S, Pokhrel P, Kate N, et al. Relapse of Tourette Syndrome with Clozapine in a Patient of Paranoid Schizophrenia. *J Clinic Case Reports.* 2012;2:e112
37. Tsui MCM. Review of the Effects of Yoga on People with Schizophrenia. *J Yoga Phys Ther.* 2012; S1-001.
38. Rosedale MT, Jacobson M, Moller MD, et al. Transcranial Direct Current Stimulation to Enhance Cognition and Functioning in Schizophrenia. *J Nov Physiother.* 2014;4:191.
39. Jan L, Chalany J. Clozapine for Treating Pharmacoresistant Schizophrenia among Elders. *J Clin Diagn Res.* 2014;2:101
40. Sakai M, Kashiwahara M, Kakita A, et al. An Attempt of Non-human Primate Modeling of Schizophrenia with Neonatal Challenges of Epidermal Growth Factor. *J Addict Res Ther.* 2014;5:170.
41. Hood S, Hudaib AR. A Patient with a Pancreatic Endocrine Tumor develops Chronic Schizophrenia: Report of a Case. *J Clin Case Rep.* 2013;4:328.
42. Zhang J, Chu KW, Hazlett EA, et al. A FDG-PET and fMRI Study on Glucose Metabolism and Hemodynamic Response during Visual Attentional Performance in Schizophrenia. *OMICS J Radiol.* 2013;2:149.
43. Ikemoto K. D-Neuron: Is it Ligand-Producing Neuron of Taar1? From Schizophrenia Research. *J Community Med Health Edu.* 2013;3:221.
44. Shankar GS, Yuan C. Effects of 5HT_{2c} Blockade of Dibenzodiazepines on Thyroid Levels in Patients with Schizophrenia or Schizoaffective Disorder. *J Autacoids.* 2013;2:102.
45. Jacob A, Cohen S, Alavi A. Abnormal Brain Circuitry and Neurophysiology Demonstrated by Molecular Imaging Modalities in Schizophrenia. *J Alzheimers Dis Parkinsonism.* 2013;3:114.

46. Khan M, Kabadi UM. Metabolic Challenges in Schizophrenia. *J Psychol Psychother.* 2013;3:115.
47. Andreica-Săndică B. The Necessity of Family Type Interventions During First - Episode Psychosis in Schizophrenia. *J Trauma Treat.* 2013;2:e111.
48. Jang CH, Choi J, Cheol Park S. A Case of Clozapine-Resistant Schizophrenia Associated With a Large Arachnoid Cyst in the Left Sylvian Fissure. *J Psychiatry.* 2014;17:176.
49. Ahmed S. Nicotine Addiction in Schizophrenia, Availability of Better Treatment Options as are in General Population. *Int J Emerg Ment Health.* 2015;17:135.
50. Mélanie Langlois, Doré M, Laforce R. Thirty Days without a Bite: Wernicke's Encephalopathy in a Patient with Paranoid Schizophrenia. *J Neurol Disord.* 2014;2:182.
51. Ryan ME, Melzer T. Delusions in Schizophrenia: where are we and where Do we need to go?. *Int J Sch Cogn Psychol.* 2014;1:115.
52. Quliti KWA. A Case Study of Partial Seizure with Secondary Generalization Induced by Clozapine in Patient with Treatment Resistant Schizophrenia. *Brain Disord Ther.* 2014;3:145.
53. Millier A, Briquet B, Georges N, et al. Reasons for Aripiprazole Discontinuation in Schizophrenia- A Retrospective. *J Neurol Neurophysiol.* 2014;5:226.
54. Meszaros ZS, Malak YA, Zaccarini DJ, et al. Smoking Severity and Functional MRI Results In Schizophrenia: A Case-Series. *J Addict Res Ther.* 2014;5:189.
55. Werner FM. Brain Centers Involved in Schizophrenia. *J Cytol Histol.* 2014;5: i101
56. Yılmaz ED, Deveci E, Güleç H, et al. Correlation between Anxiety and Personality in Caregivers for Patients with Schizophrenia. *J Psychiatry.* 2014;17:130.
57. Park AL. Exploring the Economic Implications of a Group-Based Lifestyle Intervention for Middle-Aged Adults with Chronic Schizophrenia and Co-Morbid Type 2 Diabetes. *J Diabetes Metab.* 2014;5:366.
58. Ahmadian S, Zaeifi D. D3 as a Possible Marker Based on D1-D4 Dopamine Receptors Expression in Paranoid Schizophrenia Patients. *J Mol Biomark Diagn.* 2014;5:171.
59. Gharibzadeh S, Darvishi A, Darvishi M. Reactivation of NMDA Receptors by Synaptic Reentry Reinforcement, a Probable Cause of Auditory Hallucination in Schizophrenia. *Brain Disord Ther.* 2014;3:118.
60. Hussien ZN, Solomon H, Yohannis Z, et al. Prevalence and Associate Factors of Suicidal Ideation and Attempt among People with Schizophrenia at Amanuel Mental Specialized Hospital Addis Ababa, Ethiopia. *J Psychiatry.* 2015;18:184.
61. Singh M, Solanki RK, Bagaria B, et al. Hypothalamic-Pituitary-Adrenal (HPA) Axis Functioning among Patients with Schizophrenia: A Cross Sectional Comparative Study. *J Psychiatry.* 2015; 18:211.
62. Kaberi Bhattacharya. Cognitive Function in Schizophrenia: A Review. *J Psychiatry.* 2015; 18:187.
63. Yavasci EO, Eker SS, Cangur S, et al. Prediction of Depression in Schizophrenia: Can serum Levels of BDNF or EGF Help us?. *J Psychiatry.* 2014;17:1000156.
64. Yang C, Li W, Weiwei W, et al. A Review: Detecting Alterations of Brain Connectivity in Schizophrenia based on Structural MRI. *J Psychiatry.* 2014;17:159.
65. Tenyi T. The Importance of Research on the Relatives of Schizophrenia Patients? Towards Endophenotypic Markers. *Int J Emerg Ment Health.* 2015;17: e211.
66. Elsayed MA. Schizophrenia in Hollywood Movies. *J Mass Communicat Journalism.* 2015;5:256.

67. Ikemoto K. Dopamine Hypothesis is linked with Neural Stem Cell (NSC) Dysfunction Hypothesis by D-Cell Hypothesis (Trace Amine Hypothesis) in Etiology of Schizophrenia. *Biochem Physiol.* 2015;4:152.
68. Kamal MS, El Dine. Spotlights on Pharmacogenetics of Schizophrenia and Depressed Mood. *Gene Technol.* 2015;4:121.
69. Alshowkan A, Curtis J, White Y. Factors Affecting the Quality of Life for People with Schizophrenia in Saudi Arabia: A Qualitative Study. *J Psychiatry.* 2015;18:295.
70. Korenis P, Patel R, Gonzalez L, et al. Schizophrenia with Somatic Delusions: A Case Report. *J Psychiatry.* 2015;18:290.
71. Naguy A, Al-Mutairi H. Add-on Atomoxetine Mitigated Different Symptom Domains in a Case of Early- Onset Schizophrenia. *J Psychiatry.* 2015;18:279.
72. Kocazeybek B, Kalayci F. Assessment of Association between Schizophrenia and Chlamydiaceae Using Hill Criteria. *J Psychiatry.* 2015;18:250.
73. Zhang J, Zhang GY, Zhang C, et al. Interaction between MicroRNA-7 and its Target Genes in Schizophrenia Patients. *J Psychiatry.* 2015;18:235.
74. Gigi A, Karni D, Eilam O. Visual Impairment Affects the Perception of Reality: Visual Processing Deficits among Adolescents with Schizophrenia. *J Psychiatry.* 2015;18:232.
75. Chieffi S, Iavarone A, La Marra M, et al. Vulnerability to Distraction in Schizophrenia. *J Psychiatry.* 2015;18:228.
76. Palego L, Betti L, Giannaccini G. Sulfur Metabolism and Sulfur-Containing Amino Acids Derivatives ? II: Autism Spectrum Disorders, Schizophrenia and Fibromyalgia. *Biochem Pharmacol (Los Angel).* 2015;4:159.
77. Werner FM, Covenas R. Clinical Efficacy of Antipsychotic Drugs in the Treatment of Schizophrenia. *J Cytol Histol.* 2015;S4-013.
78. Kelleher JP. The Evolution of Schizophrenia Research and Treatment. *Int J Emerg Ment Health.* 2015;17:280.
79. Pino MC, Mariano M, Valchera A, et al. Effect of Gaze Direction on Orienting of Attention in Patients with Schizophrenia: Attention or Social Cognition Deficit? *J Depress Anxiety.* 2015;4:200.
80. Hernandez-Yáñez HD, Reyes-Tovilla JE, Juárez-Rojop IE, et al. Family Support and Adherence to Treatment in Patients Diagnosed with Schizophrenia in Tabasco, Mexico: A Case- Series Study. *J Psychiatry.* 2015;18:304.
81. Bademli K. Peer to Peer Support in Schizophrenia. *Int J Emerg Ment Health.* 2015;17: e239.
82. Morgan T. Excerpts from The Genetic Lottery: A Novel Look at Schizophrenia. *Int J Emerg Ment Health.* 2015;17:233.
83. Inanaga K. Recovery from Schizophrenia with Bioactive Substances in *Heridium erinaceum*. *Int J Sch Cog Psychol.* 2015;S1:003.
84. Tao J, Zeng Q, Liang J, et al. Effects of Cognitive Rehabilitation Training on Schizophrenia: 2 Years of Follow-Up. *J Psychiatry.* 2015;8(9):16089-16094.
85. Fandiño-Franky J. Neuroplasticity and Antipsychotics in Treatment of Schizophrenia. *J Neurol Disord.* 2015;3:e115.
86. Bademli K. What to Know about Schizophrenia Caregiver Support. *Int J Emerg Ment Health.* 2015;17:218.
87. Bonnard-Couton V, Dor E, Santos A, et al. Emotional Face Perception: Event-Related Potentials (ERPS) Contribution to Differentiate Schizophrenia and Autism Spectrum Disorders in Adolescents. *Autism Open Access.* 2015;5:156.

88. Ikemoto K, Nishimura A. Lectin-Positive Spherical Deposits (SPD) Detected in the Molecular Layer of Hippocampal Dentate Gurus of Schizophrenia. *J Neurol Neurophysiol*. 2015;6:328.
89. Bartova L, Dold M, Rieder NP, et al. Ultra-High-Dose Long-Acting Injectable Aripiprazole in Chronic Refractory Schizophrenia: A Case Report. *J Clin Toxicol*. 2015;5:270.
90. Palit S. The Challenge of Overcoming Schizophrenia and a True Vision for the Future. *Neurochem Neuropharm*. 2015;1:104.
91. DiBenedetti DB, Brown MT, Danchenko N, et al. Assessing Patient and Caregiver Experiences with Symptoms and Behaviors Associated with Schizophrenia. *J Depress Anxiety*. 2016;5:240.
92. Ribolsi M, Lorenzo GD, Niolu C, et al. Non Invasive Brain Stimulation to Improve Metaphoric Speech Processing in Schizophrenia: A Pilot Study. *J Neurol Neurophysiol*. 2016;7:375.
93. Iqbal MZ, Ejaz M. Case Study of Schizophrenia (Paranoid). *J Clin Case Rep*. 2016;6:779.
94. De Berardis D. Second Generation Long-acting Injectable Antipsychotics as a First-line Treatment of First Episode Schizophrenia:Lights and Shadows. *J Neuropsychopharmacol Mental Health*. 2016;1:e106.
95. Stefano Barlati, et al. Autism Spectrum Disorder and Schizophrenia: Do They Overlap?. *Int J Emerg Ment Health*. 2016;18:318.
96. Mamo ES, Gelaw BK, Tegegne GT, et al. Medication Adherence among Patients with Schizophrenia Treated with Antipsychotics at Adama Hospital, East Shoa Zone, Oromia Regional State. *Adv Pharmacoepidemiol Drug Saf*. 2016;5:2.
97. Shakeel S, Naveed S, Iffat W, et al. Pharmacy Students Attitude and Stigmatization of People with Schizophrenia in Pakistan. *J Bioequiv Availab*. 2016;8:108-111.
98. Penaherrera CA, Duarte MC. Schizophrenia and Social Cognition: A Review of Concepts and Treatment Options. *J Socialomics*. 2016;5:150 .
99. Ray P, Khess CRJ. Level of Insulin Resistance in Schizophrenia Patients and Its Association with Treatment with Antipsychotics. *J Neuropsychopharmacol Mental Health*. 2016;1:104.
100. Manzano JM, Munoz JJ, Santos JM, et al. MEG resting-state differences as a marker of clinical subtype in schizophrenia. *Neuropsychiatry (London)*. 2017;7(2),172-178.